Apontis Pharma AG (APPH.F)
| Previous close | 13.30 |
| Open | 13.35 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 13.35 - 13.35 |
| 52-week range | 10.60 - 27.30 |
| Volume | |
| Avg. volume | 163 |
| Market cap | 113.475M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.17 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 29.00 |
- EQS Group
APONTIS PHARMA launches two new single pills - medium-term revenue potential of EUR 8.2 million
DGAP-News: APONTIS PHARMA AG / Key word(s): Product LaunchAPONTIS PHARMA launches two new single pills - medium-term revenue potential of EUR 8.2 million 25.05.2022 / 07:30 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA launches two new single pills - medium-term revenue potential of EUR 8.2 million Medium-term revenue potential of Tonotec Lipid: EUR 5.0 million Medium-term revenue potential of AmloAtor: EUR 3.2 million Potential patient group of 750,000 peo
- EQS Group
APONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda items with large majorities
DGAP-News: APONTIS PHARMA AG / Key word(s): AGM/EGMAPONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda items with large majorities 12.05.2022 / 15:00 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda items with large majoritiesMonheim am Rhein, 12 May 2022. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single
- EQS Group
APONTIS PHARMA continues strong profitable growth in Q1 2022
DGAP-News: APONTIS PHARMA AG / Key word(s): Quarterly / Interim StatementAPONTIS PHARMA continues strong profitable growth in Q1 2022 10.05.2022 / 07:30 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA continues strong profitable growth in Q1 2022 Single Pill revenues +40% to EUR 8.7 million remain main growth driver Single Pill revenue share increases to 61% (3M 2021: 57%) Total revenues grow faster than pharma sector by 31% to EUR 14.3 million EBITDA increas
